PHARMA

Indegene Ltd shares jump 2.84% as SEBI disclosure received for BPC Genesis Fund I SPV

By Ali Abbas Najmi •
Indegene Ltd received a disclosure from BPC Genesis Fund I-A SPV Ltd on 7 August 2026, under SEBI Regulation 29(2), for scrip code 544172, concerning substantial acquisition of shares.

Why did Indegene Ltd shares jump today?

Shares of Indegene Ltd rose sharply today, jumping to a current price of . The significant uptick in the stock, as of , is directly linked to a regulatory announcement that has likely boosted investor confidence.

The trigger for this movement was a disclosure made by , a Cayman Islands-based investment entity. The company submitted a formal disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, to both the BSE and NSE exchanges. This regulation typically pertains to announcements made in advance of a proposed acquisition of shares, signaling that the fund is planning a significant investment or increase in its stake in Indegene.

In simple terms, this public disclosure acts as a notice to the market that a prominent institutional investor is poised to become a larger shareholder in the company. Such a move is often interpreted as a strong vote of confidence in Indegene's business prospects, future growth, and management, which in turn attracts positive sentiment and buying interest from other market participants, driving the share price higher.

What does Indegene Ltd do?

Indegene Limited is a publicly traded company with stock listed on both the BSE Limited and the National Stock Exchange of India Limited, under the trading symbol INDGN. Its registered corporate office is located within Manyata Embassy Business Park in Bengaluru, Karnataka, India.

The company's shares are the subject of a formal disclosure under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, submitted by the investment entity BPC Genesis Fund I-A SPV Limited. This regulatory filing indicates activity related to the acquisition or holding of a substantial number of equity shares in Indegene Limited.

Indegene Ltd Financials

In Crores
1003
80
Mar 2026
1063
116
Jun 2026
Revenue
Net Profit

Indegene Ltd's revenue increased from ₹1003.4 Crores in March 2026 to ₹1063.1 Crores in June 2026, reflecting a growth of approximately 5.9%. Concurrently, the company's profit also saw a significant rise from ₹79.7 Crores to ₹116.2 Crores over the same period, indicating a growth of about 45.8%. The financial data demonstrates a positive trend, with growth recorded in both revenue and profit metrics from the March 2026 to the June 2026 quarter.

Indegene Ltd Shareholding Pattern

Holdings
Promoter
0.0%
FIIs
9.92%
DIIs
8.74%
Public
81.34%

Promoter holding stands at 0.0% of the total share capital. Foreign Institutional Investors (FIIs) hold 9.92% stake in the company, while Domestic Institutional Investors (DIIs) hold 8.74%. Public shareholders hold the remaining 81.34% stake in Indegene Ltd.

Indegene Ltd FAQs

Q: Why did Indegene shares jump 2.84% today?

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BPC Genesis Fund I- A SPV Ltd. This corporate action caught investor attention, leading to increased trading activity in the stock.

Q: What is the shareholding pattern of Indegene Ltd?

As per the latest data, promoters hold 0.0% stake in Indegene Ltd, while FII holding stands at 9.92%. Domestic institutional investors hold 8.74%, and public shareholders account for 81.34% of the equity.

Q: What is the current stock price of Indegene Ltd?

Indegene Ltd shares are currently trading at ₹569.85, recording a gain of 2.84% from the previous close.

Q: What is the market capitalization of Indegene Ltd?

The company currently has a market capitalization of ₹13706.52 crore, reflecting its valuation in the Indian equity market.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. The stock prices mentioned are as of the time of writing. Ali Abbas Najmi and the publisher do not hold any positions in the stocks mentioned. Please consult a SEBI-registered financial advisor before making any investment decisions.